Group One Trading, L.P. Nrx Pharmaceuticals, Inc. Transaction History

Group One Trading, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.29 - $0.7 $5,292 - $12,775	-18,251 Reduced 95.27%	907 $0
Q3 2023 Nov 09, 2023	SELL	$0.23 - $0.5 $1,311 - $2,850	-5,700 Reduced 22.93%	19,158 $4,000
Q2 2023 Aug 09, 2023	BUY	$0.46 - $0.89 $1,624 - $3,143	3,532 Added 16.56%	24,858 $11,000
Q1 2023 May 12, 2023	SELL	$0.66 - $1.4 $16,617 - $35,249	-25,178 Reduced 54.14%	21,326 $14,000
Q4 2022 Feb 09, 2023	SELL	$0.79 - $9.19 $52,993 - $616,465	-67,080 Reduced 59.06%	46,504 $51,000
Q3 2022 Nov 09, 2022	SELL	$0.2 - $8.07 $11,867 - $478,865	-59,339 Reduced 34.32%	113,584 $84,000
Q2 2022 Aug 11, 2022	BUY	$0.51 - $2.42 $70,907 - $336,464	139,035 Added 410.28%	172,923 $104,000
Q1 2022 May 12, 2022	BUY	$2.45 - $5.04 $67,691 - $139,250	27,629 Added 441.43%	33,888 $83,000
Q4 2021 Feb 11, 2022	SELL	$4.5 - $11.91 $5,917 - $15,661	-1,315 Reduced 17.36%	6,259 $30,000
Q3 2021 Nov 12, 2021	BUY	$8.52 - $24.77 $64,530 - $187,607	7,574 New	7,574 $70,000

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $111M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.